Multi-Electrode Array (MEA) Offers New Route for Type 2 Diabetes Drug Development and Ability to Elucidate Beta Cell Pathophysiology HOLLISTON, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Multi Channel Systems (MCS), a subsidiary of Harvard Bioscience, Inc.

PhysioTel™ Digital L03 and L04 Designed to Improve Animal Welfare in Large Animal Models ST. PAUL, Minn. and HOLLISTON, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) and the global leader in wireless physiologic

HOLLISTON, Mass. , April 23, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its first quarter 2018 after market trading hours on Wednesday, May 2, 2018 .

Third Consecutive Quarter of Top Line Organic Growth and DSI Acquisition Position Company for Further Improvements in 2018

HOLLISTON, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2017 after market trading hours on Thursday, March 1, 2018.

HOLLISTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced today that the Company has completed the previously announced acquisition of

 Reports 2018 Guidance -Conference Call and Webcast Scheduled for Tuesday, January 23 at 7:30 AM ET- HOLLISTON, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance

HOLLISTON, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and nine months ended September 30, 2017.

HOLLISTON, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, appointed Katherine Eade and Thomas Loewald as Class II directors of the Board of

HOLLISTON, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2017 after market trading hours on Thursday, October 26, 2017.